passages: 2538
passages: document
passages: Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome . BACKGROUND Raised triglycerides ( TG ) , decreased high-density lipoprotein cholesterol ( HDL-C ) levels and a predominance of small dense low density lipoproteins ( sdLDL ) are characteristics of the metabolic syndrome ( MetS ) . OBJECTIVE To compare the effect of high-dose rosuvastatin monotherapy with moderate dosing combined with fenofibrate or ω-3 fatty acids on the lipoprotein subfraction profile in patients with mixed dyslipidaemia and MetS . METHODS We previously randomised patients with low-density lipoprotein cholesterol ( LDL-C ) > 160 and TG > 200 mg/dl to rosuvastatin monotherapy 40 mg/day ( R group , n = 30 ) or rosuvastatin 10 mg/day combined with fenofibrate 200 mg/day ( RF group , n = 30 ) or ω-3 fatty acids 2 g/day ( Rω group , n = 30 ) . In the present study , only patients with MetS were included ( 24 , 23 and 24 in the R , RF and Rω groups respectively ) . At baseline and after 12 weeks of treatment , the lipoprotein subfraction profile was determined by polyacrylamide 3 % gel electrophoresis . RESULTS The mean LDL size was significantly increased in all groups . This change was more prominent with RF than with other treatments in parallel with its greater hypotriglyceridemic capacity ( p < 0.05 compared with R and Rω ) . A decrease in insulin resistance by RF was also noted . Only RF significantly raised HDL-C levels ( by 7.7 % , p < 0.05 ) by increasing the cholesterol of small HDL particles . The cholesterol of larger HDL subclasses was significantly increased by R and Rω . CONCLUSIONS All regimens increased mean LDL size ; RF was the most effective . A differential effect of treatments was noted on the HDL subfraction profile .
entities: 2539
entities: Intervention_Pharmacological
entities: rosuvastatin
entities: 2540
entities: Intervention_Pharmacological
entities: fenofibrate
entities: 2541
entities: Intervention_Pharmacological
entities: ω-3 fatty acids
entities: 2542
entities: Intervention_Pharmacological
entities: rosuvastatin
entities: 2543
entities: Intervention_Pharmacological
entities: fenofibrate
entities: 2544
entities: Intervention_Pharmacological
entities: ω-3 fatty acids
entities: 2545
entities: Intervention_Pharmacological
entities: rosuvastatin
entities: 2546
entities: Intervention_Pharmacological
entities: rosuvastatin
entities: 2547
entities: Intervention_Pharmacological
entities: fenofibrate
entities: 2548
entities: Intervention_Pharmacological
entities: ω-3 fatty
entities: 2549
entities: Outcome_Physical
entities: lipoprotein subfraction profile
entities: 2550
entities: Outcome_Physical
entities: lipoprotein subfraction profile
entities: 2551
entities: Outcome_Physical
entities: lipoprotein subfraction
entities: 2552
entities: Outcome_Physical
entities: mean
entities: 2553
entities: Outcome_Physical
entities: insulin resistance
entities: 2554
entities: Outcome_Physical
entities: cholesterol of larger HDL
entities: 2555
entities: Participant_Condition
entities: patients with mixed dyslipidaemia and metabolic syndrome
entities: 2556
entities: Participant_Condition
entities: patients with mixed dyslipidaemia and MetS
entities: 2557
entities: Participant_Condition
entities: patients with low-density lipoprotein cholesterol ( LDL-C ) > 160 and TG > 200 mg/dl
entities: 2558
entities: Participant_Condition
entities: patients with MetS